HAWKINS INC. - 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2007, and the nine-month period ended on the same date. Hawkins, Inc. is a Minnesota-based company operating in three reportable segments: Industrial, Water Treatment, and Pharmaceutical. The company manufactures and sells chemical products, including bulk chemicals like caustic soda, antimicrobial products, and pharmaceutical ingredients.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2007 | Nine Months Ended Dec 31, 2007 |
|---|---|---|
| Sales | $48,471,758 | $145,238,339 |
| Gross Margin | $9,135,941 (18.8%) | $32,841,991 (22.6%) |
| Income from Operations | $2,177,452 (4.5%) | $10,889,573 (7.5%) |
| Net Income | $1,506,953 | $7,379,442 |
| Earnings Per Share (Basic/Diluted) | $0.15 | $0.72 |
| Cash and Cash Equivalents | $9,410,450 | $9,410,450 |
| Investments Available-for-Sale | $10,254,748 | $10,254,748 |
| Total Current Assets | $59,587,965 | $59,587,965 |
| Total Current Liabilities | $17,720,205 | $17,720,205 |
| Net Cash Provided by Operating Activities | N/A | $6,925,567 |
| Net Cash Used in Investing Activities | N/A | $(4,396,990) |
| Net Cash Used in Financing Activities | N/A | $(4,711,066) |
Debt and Liquidity: The company reported no long-term debt on the balance sheet. Total shareholders' equity was $85,798,110. The company maintains a strong liquidity position with cash and short-term investments totaling approximately $19.7 million.
Material Changes vs. Prior Period
- Sales Growth: Sales increased 30.9% for the quarter and 20.3% for the nine-month period compared to the prior year. The Industrial segment drove this growth with a 38.8% quarterly increase, aided by the acquisition of Trumark, Inc. and higher volumes of bulk chemicals.
- Profitability: Net income surged 379.5% for the quarter ($1.51M vs $0.31M) and 17.9% for the nine months ($7.38M vs $6.26M). Operating income for the quarter jumped from $274,589 to $2,177,452.
- Margins: Gross margin percentage decreased slightly for the quarter (18.8% vs 18.9%) and nine months (22.6% vs 24.0%) due to a shift toward lower-margin, higher-volume products and rising raw material costs, particularly caustic soda.
- Acquisition: The company completed the acquisition of Trumark, Inc. on May 31, 2007, for approximately $6.0 million in cash and stock. This added antimicrobial product capabilities to the Industrial segment.
- Expenses: Selling, general, and administrative (SG&A) expenses increased significantly, partly due to costs associated with implementing a new Enterprise Resource Planning (ERP) system and acquisition-related fees.
Guidance, Outlook, and Risks
- Outlook: Management expects capital expenditures to continue at similar levels for the remainder of the fiscal year. ERP implementation costs are expected to continue in the fourth quarter before gradually decreasing in fiscal 2009.
- Investment Portfolio: The company holds fixed income securities and a mutual fund. A mutual fund was sold in January 2008, with a gain of approximately $240,000 expected to be recognized in the fourth quarter of fiscal 2008.
- Risks:
- Commodity Prices: The company is subject to cyclical fluctuations in commodity chemical prices (e.g., caustic soda). While they attempt to pass costs to customers, there is no assurance they can do so.
- Regulatory: The Pharmaceutical segment previously faced FDA selling restrictions, which were largely resolved by the end of the period. Future regulatory changes remain a risk.
- Interest Rate Risk: The investment portfolio is subject to interest rate risk, though the company intends to hold fixed income securities to maturity.
- Unusual Items: Approximately $300,000 in non-recurring expenses were incurred related to the Trumark acquisition. Consulting and contractor fees for the ERP system totaled approximately $1.4 million for the nine-month period.
Key Facts for Investor Verification
- Verify the sustainability of the 30.9% quarterly sales growth, particularly the contribution from the Trumark acquisition and bulk chemical volumes.
- Monitor the impact of rising raw material costs on gross margins, especially in the Industrial segment where margins compressed to 14.4%.
- Track the ongoing costs and benefits of the new ERP system implementation, which significantly impacted SG&A expenses.
- Confirm the resolution of any remaining FDA-related issues in the Pharmaceutical segment to ensure full sales recovery.
- Review the company's ability to maintain its dividend policy ($0.24 per share for the nine months) given the cash outflows for dividends and acquisitions.